A real-world study of PARP inhibitors in 75 patients with platinum-sensitive recurrent ovarian cancer from China

Jinghong Chen,Mengpei Zhang,Kemin Li,Yuanqiong Duan,Xiaojuan Lin,Lan Zhong,Qintong Li,Rutie Yin
DOI: https://doi.org/10.3389/fonc.2023.1300199
IF: 4.7
2024-01-09
Frontiers in Oncology
Abstract:Objective: The aim of this study is to assess the efficacy and safety of poly (ADP-ribose) polymerase inhibitor (PARPi) as a maintenance therapy for patients with platinum-sensitive recurrent epithelial ovarian cancer (PSROC) at the largest center of gynecologic oncology in Western China. Patients and methods: The efficacy of PARPi was evaluated by progression-free survival (PFS) and overall survival (OS) in this real-world single-center retrospective cohort study conducted at West China Second University Hospital. The safety of PARPi was assessed using Common Terminology Criteria for Adverse Events Version 5.0. Results: In this study, we included a total of 75 eligible patients, of which 54 (72.0%) received olaparib and 21 (28.0%) received niraparib. Among these patients, 24 (32.0%) had breast cancer susceptibility gene (BRCA) mutations, 27 (36.0%) achieved complete response after their last platinum-based therapy, and 22 (29.3%) had previously received ≥3 rd -line chemotherapy. The median progression-free survival (mPFS) was 19.1 months (95% CI 8.5-29.7), and the median overall survival (mOS) had not been reached. Log-rank analysis revealed that age (<65 years old V.S. ≥65 years old) and previous lines of chemotherapy (2 nd -line V.S. 3 rd -line V.S. ≥4 th -line) were associated with prolonged PFS ( P < 0.05). However, multivariate COX regression analysis did not identify any independent factors associated with prognosis ( P > 0.05). The most common grade≥3 adverse events in the olaparib group were anemia, thrombocytopenia, and leukopenia, while in the niraparib group, they were anemia and thrombocytopenia. Conclusion: This study confirmed that olaparib and niraparib are effective and tolerate for PSROC in real-world settings. At the follow-up endpoint, no independent prognostic factor associated with prolonged PFS was identified.
oncology
What problem does this paper attempt to address?